Cabenuva vs Apretude
A side-by-side look at two hiv medications advertised on TV. Informational only — not medical advice.
| US Cabenuva | US Apretude | |
|---|---|---|
| Generic name | cabotegravir/rilpivirine | cabotegravir |
| Drug class | Integrase Inhibitor / NNRTI (Long-Acting Injectable) | Integrase Inhibitor (Long-Acting Injectable PrEP) |
| Treats | HIV-1 infection | HIV prevention (PrEP) |
| Category | HIV | HIV |
| Manufacturer | ViiV Healthcare | ViiV Healthcare |
| Year approved | 2021 | 2021 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Injection site reactions, Fever, Fatigue, Headache | Injection site reactions, Headache, Fever, Fatigue |
Frequently asked questions
Is Cabenuva or Apretude better?
Neither is universally "better." Cabenuva (cabotegravir/rilpivirine) and Apretude (cabotegravir) are both used for hiv, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Cabenuva and Apretude?
Cabenuva is a Integrase Inhibitor / NNRTI (Long-Acting Injectable) made by ViiV Healthcare, while Apretude is a Integrase Inhibitor (Long-Acting Injectable PrEP) made by ViiV Healthcare. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Cabenuva has the larger estimated TV advertising budget of the two.